Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Cholangiocarcinoma × tremelimumab × Clear all

Phase

Status

Completed 3 Recruiting 2 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3 Prostatic Neoplasms 2 Melanoma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Testicular Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Precancerous Conditions 1 Ovarian Neoplasms 1 Neoplasms, Germ Cell and Embryonal 1 Muscle-invasive Bladder Cancer 1 Multiple Myeloma 1 Mesothelioma 1 Hepatitis C 1 Endometrial Neoplasms 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Cholangiocarcinoma 1 Adenocarcinoma, Follicular 1

Interventions

Gemcitabine 20 Cisplatin 13 pembrolizumab 5 Fluorouracil 5 pemigatinib 3 Radiotherapy 3 Drug Therapy 3 aldesleukin 2 Radiosurgery 2 Oxaliplatin 2 Nivolumab 2 Liver Transplantation 2 Leucovorin 2 Dexamethasone 2 Cholangiopancreatography, Endoscopic Retrograde 2 Carboplatin 2 Capecitabine 2 trifluridine tipiracil drug combination 1 tremelimumab 1 trametinib 1 spartalizumab 1 seribantumab 1 peginterferon alfa-2b 1 pazopanib 1 padeliporfin 1 ivosidenib 1 irinotecan sucrosofate 1 infigratinib 1 gemcitabine-oxaliplatin regimen 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04989218 2024-11-05

ICC

University of Alabama at Birmingham

Phase 1/2 Terminated

1 enrolled 11 charts

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡